Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Topic Tracks*:

Organ Site Tracks*:

Showing session: reset

Clinical Trials Using PARP Inhibitors

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8
DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer
Joaquin Mateo
The Institute of Cancer Research & The Royal Marsden NHS Trust, London, United Kingdom
from AACR Annual Meeting 2015 on April 21, 2015 10:30 AM-12:40 PM
Discussant
William K. Kelly
Thomas Jefferson Univ. Kimmel Cancer Ctr., Philadelphia, PA, United States
from AACR Annual Meeting 2015 on April 21, 2015 10:30 AM-12:40 PM
Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients
Vasiliki Michalarea
Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom
from AACR Annual Meeting 2015 on April 21, 2015 10:30 AM-12:40 PM
Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort
Ursula A. Matulonis
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2015 on April 21, 2015 10:30 AM-12:40 PM
Discussant
Geoffrey I. Shapiro
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2015 on April 21, 2015 10:30 AM-12:40 PM
Combination of the PARP inhibitor veliparib (ABT888) with irinotecan in patients with triple negative breast cancer: Preliminary activity and signature of response
Patricia M. LoRusso
Yale Cancer Center, New Haven, CT, United States
from AACR Annual Meeting 2015 on April 21, 2015 10:30 AM-12:40 PM
Pharmacokinetic/pharmacodynamic study of sequence specificity of the PARP inhibitor, olaparib and carboplatin in recurrent women’s cancers
Victoria L. Chiou
Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States
from AACR Annual Meeting 2015 on April 21, 2015 10:30 AM-12:40 PM
Discussant
Yves G. Pommier
NCI-CCR, Bethesda, MD, United States
from AACR Annual Meeting 2015 on April 21, 2015 10:30 AM-12:40 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8